- Home
- INZY vs CDLX Comparison
INZY vs CDLX Comparison
Compare INZY & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- CDLX
- Stock Information
- Founded
- INZY 2015
- CDLX 2008
- Country
- INZY United States
- CDLX United States
- Employees
- INZY N/A
- CDLX N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- CDLX Computer Software: Programming Data Processing
- Sector
- INZY Health Care
- CDLX Technology
- Exchange
- INZY Nasdaq
- CDLX Nasdaq
- Market Cap
- INZY 256.3M
- CDLX 98.2M
- IPO Year
- INZY 2020
- CDLX 2018
- Fundamental
- Price
- INZY $4.00
- CDLX $1.80
- Analyst Decision
- INZY Buy
- CDLX Hold
- Analyst Count
- INZY 9
- CDLX 5
- Target Price
- INZY $15.22
- CDLX $3.50
- AVG Volume (30 Days)
- INZY 989.2K
- CDLX 1.1M
- Earning Date
- INZY 08-05-2025
- CDLX 08-06-2025
- Dividend Yield
- INZY N/A
- CDLX N/A
- EPS Growth
- INZY N/A
- CDLX N/A
- EPS
- INZY N/A
- CDLX N/A
- Revenue
- INZY N/A
- CDLX $272,588,000.00
- Revenue This Year
- INZY N/A
- CDLX N/A
- Revenue Next Year
- INZY N/A
- CDLX $5.51
- P/E Ratio
- INZY N/A
- CDLX N/A
- Revenue Growth
- INZY N/A
- CDLX N/A
- 52 Week Low
- INZY $0.72
- CDLX $1.22
- 52 Week High
- INZY $6.24
- CDLX $9.48
- Technical
- Relative Strength Index (RSI)
- INZY 82.67
- CDLX 52.34
- Support Level
- INZY $3.94
- CDLX $1.59
- Resistance Level
- INZY $3.97
- CDLX $1.83
- Average True Range (ATR)
- INZY 0.01
- CDLX 0.20
- MACD
- INZY -0.08
- CDLX 0.00
- Stochastic Oscillator
- INZY 100.00
- CDLX 44.12
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
About CDLX Cardlytics Inc.
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.